HC Wainwright Reiterates Neutral Recommendation on Co-Diagnostics with 482.52% Upside Potential.
AI Summary1 min read
TL;DR
HC Wainwright reiterates a Neutral rating on Co-Diagnostics, projecting a 482.52% price increase to $2.04/share and a 201.25% revenue rise to $2MM.
Tags
Co-diagnosticsHC WainwrightCo-DiagnosticsNeutral RecommendationStock AnalysisPrice Target
HC Wainwright & Co. reiterated its coverage of Co-Diagnostics with a Neutral recommendation. Analysts forecast an average one-year price target of $2.04/share, a 482.52% increase from its latest closing price of $0.35/share. The projected annual revenue for Co-Diagnostics is $2MM, a 201.25% increase, and the projected annual non-GAAP EPS is 0.38.
